Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Dysregulation of brain iron homeostasis is central to early neuropathological events in Alzhei mer's disease (AD), including oxidative stress, inflam matory processes, amyloid deposition, tau phosphory lation, and neuronal cell cycle regulatory failure, leading to apoptosis. Also, there is a direct link between iron metabolism and AD pathogenesis, demonstrated by the presence of an iron‐responsive element in the 5′ UTR of the amyloid precursor protein transcript. As a consequence of these findings, a new paradigm is emerging that includes the development of iron‐chelating neuroprotective‐neurorescue drugs with multimo dal functions, acting at various pathological brain tar gets. This concept is challenging the widely held assumption that “silver bullet” agents are superior to “dirty drugs” in drug therapy for neurodegenerative diseases. At best, the so‐called magic bullets exhibit moderate symptomatic activity without modifying the course of disease progression. The present review elaborates on conventional and novel therapeutic tar gets of various multifunctional iron‐chelating drugs ( e.g., chemically designed compounds; natural polyphe nols) that address multiple central nervous system etiologies in AD, aimed at preventing or slowing disease evolution. A similar approach in drug design is being investigated for treatment of cancer, AIDS, cardiovas cular diseases, and depression.—Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H. Mandel, S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J . 22, 1296–1305 (2008)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The benefits of administration of desferrioxamine in Alzheimer’s, for instance, have been known for nearly 20 years (Crapper McLachlan et al. 1991), benefits since observed with other iron chelators”
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“Both extracellular amyloid plaques and intracellular NFTs are central pathological hallmarks of AD (33).”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Self-citationCherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“burden and slowed the rate of cognitive decline (8).”
BackgroundMitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“drial abnormalities (55); activation of select signal”
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
Smith, M. A., Harris, P. L. R., Sayre, L. M., & Perry, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9866 · Cited by 1,355
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 1×
“reduction in plasma amyloid-beta (A ) peptide A (1–42) and cognitive decline in AD patients (7), while in trans-”
BackgroundTargeting Multiple Signaling Pathways by Green Tea Polyphenol (−)-Epigallocatechin-3-Gallate
Khan, N., Afaq, F., Saleem, M., Ahmad, N., & Mukhtar, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3636 · Cited by 820
Intramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., Wu, Y.-Z., Mandelkow, E.-M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002466200 · Cited by 723
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature · doi:10.1038/21650 · Cited by 721
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Townsend, K., Zeng, J., Morgan, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1521-05.2005 · Cited by 713
Ono, K., Yoshiike, Y., Takashima, A., Hasegawa, K., Naiki, H., & Yamada, M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01976.x · Cited by 681
DNA Replication Precedes Neuronal Cell Death in Alzheimer's Disease
Yang, Y., Geldmacher, D. S., & Herrup, K. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02661.2001 · Cited by 616
Oxidative stress, cell cycle, and neurodegeneration
Klein, J. A., & Ackerman, S. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18182 · Cited by 584
Levites, Y., Weinreb, O., Maor, G., Youdim, M. B. H., & Mandel, S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00490.x · Cited by 567
Self-citationRogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207435200 · Cited by 551 · cited 2×
“(25) by a pathway similar to that of the ferritin L and H”
BackgroundCell cycle regulation in the postmitotic neuron: oxymoron or new biology?
Herrup, K., & Yang, Y. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2124 · Cited by 507
Oxidative stress, cell cycle, and neurodegeneration
Klein, J. A., & Ackerman, S. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318182 · Cited by 492
The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production
Pastorino, L., Sun, A., Lu, P.-J., Zhou, X. Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S.-H., Li, X., et al. (2006) · Nature · doi:10.1038/nature04543 · Cited by 487
Good, P. F., Perl, D. P., Bierer, L. M., & Schmeidler, J. (1992) · Annals of Neurology · doi:10.1002/ana.410310310 · Cited by 476
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459 · cited 1×
“ylation and association with microtubules (56); and”
The role of iron in cell cycle progression and the proliferation of neoplastic cells
Le, N. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00068-9 · Cited by 453 · cited 2×
“Because iron chelators have been shown to affect critical regulatory molecules involved in cell cycle arrest and proliferation (32), a therapeutic intervention with these compounds is assumed to have a profound impact on neuron preservation and AD progression.”
BackgroundRole of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration
Liou, Y.-C., Sun, A., Ryo, A., Zhou, X. Z., Yu, Z.-X., Huang, H.-K., Uchida, T., Bronson, R., Bing, G., Li, X., et al. (2003) · Nature · doi:10.1038/nature01832 · Cited by 435
Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project
Kuriyama, S., Hozawa, A., Ohmori, K., Shimazu, T., Matsui, T., Ebihara, S., Awata, S., Nagatomi, R., Arai, H., & Tsuji, I. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.355 · Cited by 428
Ahmad, N., Gupta, S., & Mukhtar, H. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1742 · Cited by 420
Ritchie, K., & Lovestone, S. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11667-9 · Cited by 387
Chen, Z. P., Schell, J. B., Ho, C.-T., & Chen, K. Y. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00108-6 · Cited by 381
Zhu, X., Rottkamp, C. A., Boux, H., Takeda, A., Perry, G., & Smith, M. A. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.10.880 · Cited by 378 · cited 1×
“include cytoskeletal phosphorylation (54); mitochon-”
Di Giovanni, S., Movsesyan, V., Ahmed, F., Cernak, I., Schinelli, S., Stoica, B., & Faden, A. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500989102 · Cited by 377
Levites, Y., Amit, T., Mandel, S., & Youdim, M. B. H. (2003) · The FASEB Journal · doi:10.1096/fj.02-0881fje · Cited by 373
Self-citationMultifunctional Activities of Green Tea Catechins in Neuroprotection
Mandel, S. A., Avramovich-Tirosh, Y., Reznichenko, L., Zheng, H., Weinreb, O., Amit, T., & Youdim, M. B. H. (2005) · Neurosignals · doi:10.1159/000085385 · Cited by 347
Self-citationZaman, K., Ryu, H., Hall, D., O'Donovan, K., Lin, K.-I., Miller, M. P., Marquis, J. C., Baraban, J. M., Semenza, G. L., & Ratan, R. R. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-22-09821.1999 · Cited by 320
Gupta, S., Hussain, T., & Mukhtar, H. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00668-9 · Cited by 304
House, E., Collingwood, J., Khan, A., Korchazkina, O., Berthon, G., & Exley, C. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6310 · Cited by 294
Atwood, C. S., Obrenovich, M. E., Liu, T., Chan, H., Perry, G., Smith, M. A., & Martins, R. N. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00174-7 · Cited by 293
Alzheimer disease, the two-hit hypothesis: An update
Zhu, X., Lee, H.-G., Perry, G., & Smith, M. A. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.10.014 · Cited by 292
Mandel, S., Amit, T., Reznichenko, L., Weinreb, O., & Youdim, M. B. H. (2006) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500156 · Cited by 291
Self-citationRogers, J. T., Leiter, L. M., McPhee, J., Cahill, C. M., Zhan, S.-S., Potter, H., & Nilsson, L. N. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6421 · Cited by 290 · cited 1×
“holo-protein in astrocytic (41) and neuroblastoma cells”
Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition
Siddiq, A., Ayoub, I. A., Chavez, J. C., Aminova, L., Shah, S., LaManna, J. C., Patton, S. M., Connor, J. R., Cherny, R. A., Volitakis, I., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504963200 · Cited by 282
Zheng, H., Weiner, L. M., Bar-Am, O., Epsztejn, S., Cabantchik, Z. I., Warshawsky, A., Youdim, M. B. H., & Fridkin, M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.10.037 · Cited by 278
Self-citationAneuploidy and DNA Replication in the Normal Human Brain and Alzheimer's Disease
Mosch, B., Morawski, M., Mittag, A., Lenz, D., Tarnok, A., & Arendt, T. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0379-07.2007 · Cited by 271
Park, D. S., Morris, E. J., Greene, L. A., & Geller, H. M. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01256.1997 · Cited by 270
Park, D. S., Farinelli, S. E., & Greene, L. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8161 · Cited by 250
Shachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., & Youdim, M. B. H. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.005 · Cited by 246
Self-citationMitotic signaling by β‐amyloid causes neuronal death
COPANI, A., CONDORELLI, F., CARUSO, A., VANCHERI, C., SALA, A., STELLA, A. M. G., CANONICO, P. L., NICOLETTI, F., & SORTINO, M. A. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.15.2225 · Cited by 245
Giovanni, A., Wirtz-Brugger, F., Keramaris, E., Slack, R., & Park, D. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.19011 · Cited by 240
Zheng, H., Gal, S., Weiner, L. M., Bar‐Am, O., Warshawsky, A., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03340.x · Cited by 214
Self-citationReznichenko, L., Amit, T., Zheng, H., Avramovich‐Tirosh, Y., Youdim, M. B. H., Weinreb, O., & Mandel, S. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03770.x · Cited by 189
Self-citationGal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185 · cited 1×
“tive action of VK28 against 6-hydroxydopamine (6OHDA) lesion in rats (13) and shown that M30 has neuroprotective activity against N-methy-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) neurotoxicity in mice (12).”
BackgroundSelf-citationIron: The Redox-active Center of Oxidative Stress in Alzheimer Disease
Castellani, R. J., Moreira, P. I., Liu, G., Dobson, J., Perry, G., Smith, M. A., & Zhu, X. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9360-7 · Cited by 180
Yang, Y., Varvel, N. H., Lamb, B. T., & Herrup, K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3707-05.2006 · Cited by 173
Mandel, S., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.06.001 · Cited by 164 · cited 1×
“Significant evidence has demonstrated that the naturally occurring flavanol epigallocatechin gallate (EGCG), which is the major constituent of green tea extract, has well-characterized antioxidant and metal (iron and copper) chelating activities and has access to the brain (2, 16, 19).”
BackgroundSelf-citationReznichenko, L., Amit, T., Youdim, M. B. H., & Mandel, S. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03085.x · Cited by 151
Self-citationNurtjahja-Tjendraputra, E., Fu, D., Phang, J. M., & Richardson, D. R. (2007) · Blood · doi:10.1182/blood-2006-10-047753 · Cited by 151
Metal and Inflammatory Targets for Alzheimers Disease
Rogers, J., & Lahiri, D. (2004) · Current Drug Targets · doi:10.2174/1389450043345272 · Cited by 149
Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis
Dedeoglu, A., Cormier, K., Payton, S., Tseitlin, K. A., Kremsky, J. N., Lai, L., Li, X., Moir, R. D., Tanzi, R. E., Bush, A. I., et al. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.08.016 · Cited by 141
Zhu, W., Xie, W., Pan, T., Xu, P., Fridkin, M., Zheng, H., Jankovic, J., Youdim, M. B. H., & Le, W. (2007) · The FASEB Journal · doi:10.1096/fj.07-8386com · Cited by 137
Self-citationFu, D., & Richardson, D. R. (2007) · Blood · doi:10.1182/blood-2007-03-076737 · Cited by 132
Avramovich‐Tirosh, Y., Amit, T., Bar‐Am, O., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04258.x · Cited by 130
Self-citationOxidative stress mechanisms and potential therapeutics in Alzheimer disease
Moreira, P. I., Siedlak, S. L., Aliev, G., Zhu, X., Cash, A., Smith, M. A., & Perry, G. L. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0242-8 · Cited by 129
Liu, Q., Zhang, J., Zhu, H., Qin, C., Chen, Q., & Zhao, B. (2006) · The FASEB Journal · doi:10.1096/fj.06-5841com · Cited by 119
The cell cycle in Alzheimer disease: A unique target for neuropharmacology
Webber, K. M., Raina, A. K., Marlatt, M. W., Zhu, X., Prat, M. I., Morelli, L., Casadesús, G., Perry, G. L., & Smith, M. A. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.03.024 · Cited by 117
Iron: A New Target for Pharmacological Intervention in Neurodegenerative Diseases
Whitnall, M., & Richardson, D. R. (2006) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.08.008 · Cited by 113 · cited 4×
“However, clioquinol is highly toxic, while the hydrophilic nature of DFO and its large molecular size limit absorption across the gastrointestinal tract and prevent it from penetrating the blood-brain barrier (BBB) (9).”
InfluentialBiswas, S. C., Shi, Y., Vonsattel, J.-P. G., Leung, C. L., Troy, C. M., & Greene, L. A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3524-06.2007 · Cited by 108
Avramovich-Tirosh, Y., Reznichenko, L., Amit, T., Zheng, H., Fridkin, M., Weinreb, O., Mandel, S., & Youdim, M. (2007) · Current Alzheimer Research · doi:10.2174/156720507781788927 · Cited by 107
Self-citationLovejoy, D., & Richardson, D. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033457557 · Cited by 98
Shin, R., Kruck, T. P. A., Murayama, H., & Kitamoto, T. (2003) · Brain Research · doi:10.1016/s0006-8993(02)03893-3 · Cited by 94
Cell cycle proteins in Alzheimer's disease: Plenty of wheels but no cycle
Bowser, R., & Smith, M. A. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4316 · Cited by 92
Copani, A., Melchiorri, D., Caricasole, A., Martini, F., Sale, P., Carnevale, R., Gradini, R., Sortino, M. A., Lenti, L., De Maria, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-10-03963.2002 · Cited by 91
Kainic acid-induced apoptosis in cerebellar granule neurons: an attempt at cell cycle re-entry
Verdaguer, E., Jordà, E. G., Canudas, A. M., Domínguez, E., Jiménez, A., Pubill, D., Escubedo, E., Camarasa, J., & Camins, A. (2002) · Neuroreport · doi:10.1097/00001756-200203250-00010 · Cited by 87
Park, K. H. J., Hallows, J. L., Chakrabarty, P., Davies, P., & Vincent, I. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0186-07.2007 · Cited by 85
BRCA1 May Modulate Neuronal Cell Cycle Re-Entry in Alzheimer Disease
Evans, T. A., Raina, A. K., Delacourte, A., Aprelikova, O., Lee, H.-G., Zhu, X., Perry, G., & Smith, M. A. (2007) · International Journal of Medical Sciences · doi:10.7150/ijms.4.140 · Cited by 67
Kim, C., & Moon, S. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.12.022 · Cited by 62
Linking cell-cycle dysfunction in Alzheimer's disease to a failure of synaptic plasticity
Arendt, T., & Brückner, M. K. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.12.005 · Cited by 62
Payton, S. M., Cahill, C. M., Randall, J., Gullans, S. R., & Rogers, J. T. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:267 · Cited by 60
Erratic expression of DNA polymerases by β‐amyloid causes neuronal death
Copani, A., Sortino, M. A., Caricasole, A., Chiechio, S., Chisari, M., Battaglia, G., Giuffrida‐Stella, A. M., Vancheri, C., & Nicoletti, F. (2002) · The FASEB Journal · doi:10.1096/fj.02-0422fje · Cited by 58
The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease
Nagy, Z. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00485.x · Cited by 56
Copani, A., Caraci, F., Hoozemans, J. J. M., Calafiore, M., Sortino, M. A., & Nicoletti, F. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.10.016 · Cited by 55
The cell cycle hypothesis of Alzheimer's disease: Suggestions for drug development
Woods, J., Snape, M., & Smith, M. A. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.12.004 · Cited by 54
Korhonen, L., Brännvall, K., Skoglösa, Y., & Lindholm, D. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10546 · Cited by 51
The dysregulation of the cell cycle and the diagnosis of Alzheimer's disease
Nagy, Z. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.11.001 · Cited by 37
Fischer, P. M. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.12.009 · Cited by 34
Bandyopadhyay, S., Ni, J., Ruggiero, A., Walshe, K., Rogers, M. S., Chattopadhyay, N., Glicksman, M. A., & Rogers, J. T. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106287271 · Cited by 34
Novel neuronal targets for the acetylcholinesterase inhibitor donepezil
Sortino, M. A., Frasca, G., Chisari, M., Platania, P., Chiechio, S., Vancheri, C., Copani, A., & Canonico, P. L. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.08.011 · Cited by 21
Alzheimer's Disease Research Enters a “New Cycle”: How Significant?
Copani, A., Sortino, M. A., Nicoletti, F., & Stella, A. M. G. (2002) · Neurochemical Research · doi:10.1023/a:1014879311761 · Cited by 16
Pahl, P. M. B., Reese, S. M., & Horwitz, L. D. (2007) · PubMed · Cited by 13
Chelation therapy: a reappraisal.
Ah, S., & Pearce, N. (1983) · PubMed · Cited by 5
Cited by
Advances in metal-induced oxidative stress and human disease
Jomova, K., & Valko, M. (2011) · Toxicology · doi:10.1016/j.tox.2011.03.001 · Cited by 3,207
“In conclusion, considring the multiple iron-operating sites in Alzheimer’s disease, ron chelators, possessing several active neuroprotective moieties an suppress the wide spectrum of oxidative stress-associated europathologies, aswell as amyloidprecursor protein (APP) transation, A generation, and amyloid plaque and n…”
BackgroundTargeting Free Radicals in Oxidative Stress-Related Human Diseases
Poprac, P., Jomova, K., Simunkova, M., Kollar, V., Rhodes, C. J., & Valko, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.005 · Cited by 1,107
“This group has incorporated structural features of both rivastigmine and donepezil into a bifunctional chelator HLA20 [5-(4-propargylpiperazin-1-ylmethyl)-8-hydroxyquinol] in which the carbamoyl moiety of rivastigmine acts a protective group to mask the quinolinol oxygen playing an important role in metal chelation [9…”
BackgroundIron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 578
“3), which can be reversed using iron chelators (Yamamoto et al. 2002; Lovell et al. 2004; Chan and Shea 2006; Amit et al. 2008).”
BackgroundKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“Iron (and in some cases copper) is also strongly implicated in a variety of neurodegenerative diseases [867] [868] [869] [870] [871] [872] [836] [873] [837] [850] [874] [875] [876] [877] [854] [878] [879] [880] [881] [842] [882] [883] [884] [885] [886] [887] [888] [889] [890] [891] [892] [893] [894] [895] [896] [897]…”
Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration
Masaldan, S., Bush, A. I., Devos, D., Rolland, A. S., & Moreau, C. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.033 · Cited by 481
“These events can be mitigated through iron chelation [2,201].”
Metadata
- Authors
- Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H., & Mandel, S.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- ORCID
- Youdim, Moussa B. H.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-11-29
- Volume
- 22
- Issue
- 5
- Pages
- 1296-1305
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2072788211
- Cited by
- 126
- References
- 89
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 6 · 2013: 9 · 2012: 12
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Alzheimer's disease, iron chelators, brain iron homeostasis, neuroprotection, neurorestoration, oxidative stress, neuroinflammation, amyloid deposition, tau phosphorylation, neuronal apoptosis, iron-responsive element, amyloid precursor protein, polyphenols, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Animals, Brain, Catechin, Cell Cycle, Humans, Hydroxyquinolines, Iron, Iron Chelating Agents, Piperazines, Amyloid beta-Protein Precursor, PC12 Cells, Neuroprotective Agents, Neurodegenerative Diseases, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.